# Scarlet Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scarlet-therapeutics

- Industry: Biotechnology
- Headquarters: Bristol, UK
- Website: www.scarlet-tx.com
- Total disclosed funding: $7.4M
- Latest round: Seed (Feb 14, 2026)
- Investors on record: 5

## About

Based in Bristol, UK, and founded in 2021 by Ash Toye and Jan Frayne, Scarlet Therapeutics Limited operates as a biotechnology research company that develops a platform that develops red blood cell-based therapies with the potential to treat a variety of diseases. In May 2026, Scarlet Therapeutics Limited raised GBP 3.2 million in seed funding from Eos, Oshen, Daft Capital, and Science Creates Ventures. 

Scarlet Therapeutics targets two rare metabolic diseases hyperammonemia and hyperoxaluria by leveraging a platform that generates novel red blood cell-based therapeutics for treating a wide range of diseases. The company’s platform also targets other metabolic diseases that require enzyme replacement therapy, cancer, and autoimmune diseases.

The company will use the May 2026 funding to advance applications of its engineered red blood cell platform, supporting in vivo proof-of-concept studies, manufacturing development, regulatory engagement, and progression toward clinical selection.

## Funding rounds

- Seed, Feb 14, 2026, $5M — Science Creates Ventures, Eos, Daft Capital, Oshen
- Seed, Aug 12, 2022, $2.4M — Meltwind, Science Creates Ventures

## Investors

- Meltwind — Seed
- Science Creates Ventures (https://capitalatlas.ai/funds/science-creates-ventures) — Seed
- Eos — Seed
- Daft Capital (https://capitalatlas.ai/funds/daft-capital) — Seed
- Oshen — Seed